• Explore /
  • Poster
  • / Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).

Abstract Poster

Authors

null

Ragini Reiney Kudchadkar

Winship Cancer Institute, Atlanta, GA

Ragini Reiney Kudchadkar , Melinda Lynne Yushak , David H. Lawson , Keith A. Delman , Michael C. Lowe , Monica Goings , Stephanie McBrien , Marjorie Mckellar , Kristin Sieja , Necia Maynard , Mandy Ford , Brian P. Pollack

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02964559

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9543)

DOI

10.1200/JCO.2018.36.15_suppl.9543

Abstract #

9543

Poster Bd #

370

Abstract Disclosures

Similar Posters

First Author: Bernard Doger de Spéville

First Author: Thiago Bueno Oliveira Sr.

First Author: Douglas Adkins

First Author: Timothy Jay Price